4th Quarter - Report

BIOCOM for BIOCOM

Firm
Client
Income
—
Expenses
$35,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Advocated to permanently repeal the medical device tax.

LobbyistCovered position, as disclosed
LAURE FABREGA CLARK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Copyright/Patent/Trademark CPT

Opposed legislation and policies that would undermine the US patent system, including "compulsory licenses"

LobbyistCovered position, as disclosed
LAURE FABREGA CLARK —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

Expressed concerns after the 10 years of data exclusivities for biologics provision was removed from the United States-Mexico-Canada Agreement

LobbyistCovered position, as disclosed
LAURE FABREGA CLARK —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Advocated against HR3, the Lower Drug Costs Now Act of 2019, because of the negative impact it would have on innovation. Co-commissioned a joint report by Vital Transformation on the impact of HR3 on California.

LobbyistCovered position, as disclosed
LAURE FABREGA CLARK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 3 (116th)

Budget/Appropriations BUD

Advocated for additional funding for the National Institutes of Health in FY2020 appropriations.

LobbyistCovered position, as disclosed
LAURE FABREGA CLARK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.